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Background: Arsenic exposure increases the risk of non-cancerous and cancerous diseases. In the Antofagasta region
in Chile, an established relationship exists between arsenic exposure and the risk of cancer of the bladder, lung and
skin. Platinum-based drugs are first-line treatments, and many works recognise selenium as a cancer-fighting nutrient.
We characterised the short-term urinary excretion amounts of arsenic, selenium and platinum in 24-h urine
samples from patients with lung cancer and those with cancer other than lung treated with cisplatin or/and
carboplatin. As - Se - Pt inter-element relationships were also investigated.
Results: The amounts of platinum excreted in urine were not significantly different between patients with lung
cancer and those with other cancers treated with cisplatin, despite the significant variation in platinum amounts
supplied from platinum-based drugs. In general, the analytical amounts of excreted selenium were greater than
those for arsenic, which could imply that platinum favours the excretion of selenium. For other types of cancers
treated with drugs without platinum, excretion of selenium was also greater than that of arsenic, suggesting an
antagonist selenium-anti-cancer drug relationship.
Conclusions: Regards the baseline status of patients, the analytical amounts of excreted Se is greater than those
for As, particularly, for cisplatin chemotherapy. This finding could imply that for over the As displacement Pt
favours the excretion of Se. The analytical amounts of excreted Se were greater than those for As, either with and
without Pt-containing drugs, suggesting an antagonist Se-anti-cancer drug relationship. However, it seemed that
differences existed between As - Se - Pt inter-element associations in patients treated for lung cancer in
comparison with those treated for cancer other than lung. Therefore, knowledge obtained in this work, can
contribute to understanding the arsenic cancer mechanism and the As - Se - Pt inter-element association for lung
cancer and other types of cancer, which in some cases respond at a linear mathematical model.
Keywords: Cancer, Platinum-based drugs chemotherapy, 24-hours urine samples, Heavy metal urine analyses,
Platinum, Arsenic, Selenium, Inter-element relationshipsBackground
There has been deterioration in the environmental
health of people living in the Region II (Antofagasta) in
Chile. This condition seems to be associated with med-
ical geology characteristics of this part of the Atacama
Desert ecosystem, geological structures in certain places
on Earth influence human health [1,2] and the* Correspondence: droman@uantof.cl
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reproduction in any medium, provided the orconsiderable mining and metallurgical activities carried
out in this geographical zone, that which exposes the
inhabitants to an increasing risk of cancer, cardiovascular
diseases, and neurological diseases. The underlying cause
could be the multi-metallic synergy of heavy metals [3].
However, arsenic (As) appears to be one of the main en-
vironmental stressors that affect the quality-of-life (QoL)
of the population [4-7]. The Antofagasta region in Chile
is an Andean highland–coastal desert ecosystem in
which large-scale mining activities have been conducted
for a long time [8]. These activities have affected the eco-
systems and the QoL of the people living there [9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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As contamination are known in several parts of the world
[10]. However, this association reaches alarming levels in
the Antofagasta region, as evidenced by the incidence of
cardiovascular diseases [5] and cancer [4,7,11]. The mor-
tality rates due to cancer in the Antofagasta region are
higher than those in any other population exposed to As
in the world [12]. Most therapeutic treatments are based
upon platinum (Pt)-based drugs [13].
There is a large body of literature on the role of trace
elements in the development of cancer [14], particularly
on the toxic effects of As on ecosystems and humans [15].
A wide variety of diseases, disorders and dysfunctions are
related specifically to the effects of heavy-metal stress, as
well as the imbalance of essential elements if humans are
exposed to several metals [3]. However, the precious heavy
metal Pt is of considerable interest, given that Pt pollution
has increased in recent years because of its emission from
automotive catalysts, its use in prostheses, and in Pt-based
anti-tumour drugs [16,17]. Administration of Pt-based
drugs has an impact at the cellular level, affecting metabol-
ism, homeostasis, and physiology in humans [18,19]. The
main side effects of the application of Pt drugs are loss of
hearing (ototoxicity), kidney dysfunction (nephrotoxicity)
[20], and resistance to anti-cancer drugs [21]. However,
the metastasis [22] represents the principal disadvantage
of these treatments.
Despite of the advances in cancer treatments, the cyto-
toxicity of chemotherapies continues to be an important
problem. Undesirable effects arising from inaccurate calcu-
lation of the Pt-based dose drugs when the body surface
area (BSA) method is applied [23], which can influence the
As, Se, and Pt inter-element interactions and therefore the
metal–creatinine ratios values and their clinical interpret-
ation. Nevertheless, failure in correctly applying the BSA
method does not account for the marked inter-patient
variation in drug handling. Therefore, drug effects such as
toxicity or consequences due to unexpected under-dosing
are unpredictable [24].
Most toxicology studies focus on a single agent, but
this approach does not reflect real-world scenarios in
which humans are exposed to multiple chemicals. The
toxicity of an element or compound may be reinforced
or weakened through its interaction with other sub-
stances. Such interactions are, in general, classified as
being ‘adversely additive’, ‘synergistic (greater than addi-
tive)’ or ‘antagonistic’ (less than additive or even acting
as antidotes to one another). Antagonistic behaviour be-
tween As-Se and Pt-Se pairs has been observed in
humans [25-29]. Hence, the level of Se in urine [30,31]
could be particularly important when assessing exposure
to heavy metals. Se would strengthen the capacity of
antioxidant-protecting components of cells (e.g., nucleic
acids) from damage of reactive oxygen species [22,30]through antioxidant Se-based enzymes such as glutathi-
one peroxidase [31] and thioredoxin reductase, which re-
quire Se(IV) for their expression [28,32]. Several
hypotheses have been stated to account for experimental
data, which indicates that Se compounds have anti-cancer
properties. However, even though evidence has been accu-
mulating in support of the ‘Se chemo protective hypoth-
esis’, definitive proof is lacking [33-38]. Otherwise, the
vulnerability of the antioxidant-protecting components of
cells can also result in side effects, metastasis [34,35] and
resistance to Pt-based drugs [21].
Evidence suggests that As inhibits the potential anti-can-
cer effects of Se, and also its interaction with essential
trace elements and other heavy metals such as copper,
zinc, cadmium, mercury, tin, lead, nickel, cobalt, antimony,
silver, gold and molybdenum [36,39]. In a study on the
urinary excretion of Se and As in pregnant women from
northern Chile, Vahter [40] found a significant association
between the urine concentrations of these elements. Drugs
that contain Pt (e.g., cisplatin, carboplatin) have been
shown to increase the biliary excretion and distribution of
Se in tissues, but Pt has not been shown to significantly in-
fluence the urinary or respiratory excretion of Se [41]. The
distribution of Se in tissues is altered by cisplatin, which
results in high concentrations of Se in the liver, kidney and
plasma, and low levels of Se in the testicles and brain. The
underlying mechanism of Se homeostasis is incompletely
understood [20].
Studies looking at urinary excretion of Pt among
patients treated with cisplatin have, on average, been
conducted 6 months to 16.8 years after treatment [42].
With the purpose of obtaining knowledge on the behav-
ior and the inter-relationships among the endogen ar-
senic-selenium pair and platinum supplied as cisplatin
and/or carboplatin, we investigated the excretion of As,
Se and Pt in 24-h urine samples after the infusion of Pt
based-drugs in five cancer patient groups coming from
the Region II (Antofagasta) - Chile. Short-term moni-
toring of urine after the first cycles of treatment with
Pt-based drugs could be a good approach for studying
the inter-element interaction among As, Se and Pt in
patients whose cancer was probably triggered by As ex-
posure. Such knowledge could contribute to: better
understanding the cancer mechanism of As and
mechanisms of Pt-based drugs based side effects [21]
and resistance to these drugs [43]; improving the opti-
mal doses calculation of the anticancer Pt-based drugs
[23] and understanding better the resistance (or permis-
siveness) to metastasis [44].
Methods
The work was carried out in accordance with the Health
Service of Antofagasta (Antofagasta, Chile) according to
ORD 4391 (20 August 2008); the study protocol was also
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Antofagasta University (CEICREV/2008).
Study population and collection of samples
Ten 24-h urine samples from cancer patients of the
Antofagasta region were collected before Pt-based drugs
chemotherapy was initiated. Ninety 24-h urine samples
from cancer patients were collected immediately after
the infusion of the Pt-base drugs; and ten 24-h urine
samples were collected from patients subjected to
chemotherapy drugs involving drugs that did not con-
tain a metal. All samples were provided by the Onco-
logical Centre of Antofagasta Regional Hospital (Region
II, Chile). The 90 cancer patients they are distributed in
the following cases: 32 lung cancer, 16 ovarian cancer,
12 cervical–uterine cancer, eight testicular cancer, five
thymus cancer, three oesophageal cancer, three gastric
cancer, three Hodgkin lymphomas, two vagina cancer,
two bladder cancer, and one each of gallbladder, tonsil,
salivary gland, and osteosarcoma cancers. The dose cal-
culation for chemotherapy had been made by the BSA
method [24]. Three of the four patients with ovarian
cancer initially treated with cisplatin were again treated
with cisplatin after 28 days, whereas the fourth patient
was treated with carboplatin. Cancer others than lung
was categorised as “others cancers”; only patients in this
group were treated with carboplatin. Samples were col-
lected between May and August 2005.
Chemicals, solutions, materials and instruments
The chemicals employed were Instra (J.T. Baker,
Phillipsburg, NJ, USA) and Suprapur (Merck, White-
house Station, NJ, USA), both of which were of trace-
element grade. Solutions were prepared in deionised
water that was subsequently distilled in quartz (conduct-
ivity, <0.5 μMHO/cm at 25°C). The deionisation was
undertaken in a deioniser with two ion-exchange
cartridges—a Metex 01506-45 and a Research 01506–35
(Cole-Parmer, Waltham, MA, USA)—connected in
tandem.
The glass materials used were sequentially treated for
24 h with 2-M solutions of hydrochloric acid and nitric
acid prepared from Merck pro analysis quality grade che-
micals. After being washed with water, the glass materials
were treated for another 24 h with a 0.025 M disodium salt
of ethylenediamine tetraacetic acid (EDTA) solution pre-
pared from Titriplex III (Merck), after which they were
rinsed with water.
Pt(II) standard dilutions were prepared from a primary
solution of Certipur (Merck) and those of Se(IV) were
prepared from a primary solution of Titrisol (Merck);
the concentration of both primary solutions was 1000
mgL–1. An intermediate 50 mgL–1 standard solution
was made, which was used to prepare the workingdilutions. Standard As solutions were prepared from a
1000 mgL–1 primary solution of disodium arsenate Titri-
sol (Merck), from which a 500 mgL–1 intermediate
standard dissolution was prepared for the working dilu-
tions. To generate arsenic hydride, 10 M chlorhydric
acid solution was used, which was prepared from Instra
(J.T. Baker). A 3% p/v sodium borohydride solution was
prepared in a 1% p/v sodium hydroxide solution, both of
which were Merck pro analysis grade quality chemicals.
Urine samples were transported in a cooler at 4–5 °C
to an acclimatised and pressurised Pre-treatment Sample
Room equipped with a laminar-flow hood (Labconco
Purifier, class II; Labconco, Kansas City, MO, USA).
Samples were microfiltered in a Nalgene system through
a Millipore cellulose ester membrane (pore size,
0.45 μm; diameter, 47 mm; Millipore, Bedford, MA,
USA). Samples were then stored at –20 °C. Immediately
before analyses of metals were carried out, the samples
were thawed and again microfiltered, this time through a
Millipore cellulose ester membrane of pore size 0.22 μm
protected by a borosilicate glass pre-filter (Advantec-
MFS, Japan) (pore size, 0.7 μm).
Matrix-matched ionic strength surrogate urine was
prepared by diluting subtidal seawater thrice with deio-
nised glass-distilled water. As a reference, the measured
average salinity of urine samples was 13 parts per thou-
sand (ppt). This was measured in a previously calibrated
Orion Ion Meter 1260 (Thermo Scientific, Waltham,
MA, USA).
Digestion of urine samples
Urine samples and controls were mineralised using the
wet method in Teflon bombs with 10 ml of nitric acid
(Instra; J.T. Baker, USA) for 2 h at 150 °C in a homemade
ceramic oven with an internal temperature sensor and
external temperature control. After the samples were
cooled, the oven was opened and an additional 0.25 mL
of perchloric acid and 0.50 mL of sulphuric acid were
added to the Teflon bombs with the digested samples;
both acids were of Suprapur grade (Merck). Samples
were then reheated under the same conditions of time
and temperature as described above. Finally, samples were
transferred to Erlenmeyer flasks and heated at 300 °C
under a gas extraction hood to eliminate excess acids.
Sample volumes were made up to 50 mL with deionised
water, and then micro-filtered through a 0.22-μm Milli-
pore membrane with a 0.7-μm fibreglass pre-filter
(Advantec-MFS, Japan).
To determine total As concentrations, 5-mL aliquots
of samples and controls were digested to semi-reflux
under a temperature programme between 85 °C and
300 °C [45]. After cooling, samples and controls were
diluted volumetrically with 0.5 M HCl prepared from
Instra quality grade chemical (J.T. Baker, USA).
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inductively coupled plasma optical emission spectrometry
(ICP–OES)
With the aim of meeting the matrix-matching condi-
tions, aliquots of three samples of digested urine were
titrated with NaOH secondary standard solution, yield-
ing an average acidity equivalent to a pH of 2. To make
compatible the matrix-matching conditions of the ana-
lytical blanks, seawater was diluted 8-fold, 10 mL of
sample was diluted to a final volume of 50 mL and,
when necessary, the solution was adjusted to pH 2 with
Instra nitric acid (J.T. Baker, USA). The bimetallic Pt–Se
standard was also subsequently prepared in this
medium.
ICP–OES calibration curves were constructed from a
50 μg/mL Pt–Se bimetallic standard at the following Pt/Se
concentrations: 100/100; 500/200; 1,000/300; 2,500/400;
and 5,000/500 ng/mL. The bimetallic standard with the
highest concentration was used to optimise the instrumen-
tal parameters. ICP–OES measurements were done on a
GBC Integra XL Spectrometer (Integra, Canberra, Austra-
lia) equipped with a spray trace nebuliser chamber and a
200 μL Micromist nebuliser (Glass Expansion, Melbourne,
Australia). Analytical-grade 5 N2 and Ar gases were used.
The optimised experimental conditions are shown in
Table 1. The baseline was adjusted with the analytical
blank solution, and quality-control (QC) tests were made
by evaluating the recovery of Pt–Se internal standard addi-
tions over blank and real samples. Before theirTable 1 Instrumental optimised conditions for urine
analysis of As, Se and Pt by means HGAAS and ICP–OES
As HG–AAS
Bandpass width 2 nm
Bandpass height Normal
Lamp current 8.0 mA
Backup current 30 mA
Temperature EHG 3000 920°C
N2 flow 45–50 mL/min
Time signal stabilisation 60 s
Reading time 10 s
Pt–Se ICP–OES
Spectral line of Pt 265.945 nm
Spectral line of Se 196.026 nm
Nebulising flow 0.40 L/min
Line detection height 6.8 mm
Pump 17.0 rpm
Power 1200 W
Auxiliary gas 0.6 L/min
Ar feed 12.0 L/min
Nebulising chamber Spray trace; Micromist nebuliser at 200 μL/minmeasurement, urine samples of patients underwent the
procedures and analytical methods described above.
Determination of total As in urine by hydride-generation
atomic absorption spectrometry (HGAAS)
Determination of As was undertaken using an atomic ab-
sorption spectrophotometer (GBC 909 AA; GBC Vic-
toria, Australia) equipped with a continuous-flow
hydride generator (GBC HG 3000) and a electrothermal
atomisation system (GBC EHG 3000). GBC quartz cells
and an As-boosted current lamp from Photron (Narre
Warren, Victoria, Australia) were also used. The opti-
mized conditions for measuring As through HGAAS are
presented in Table 1. Multiple-standard-addition meth-
odology was applied, for which an intermediate 500 mg/L
standard solution was prepared in 0.5 M HCl from a pri-
mary standard solution (Titrisol; Merck). Additions from
this solution were made to surrogate-sample urine, which
had been made up to 2.0 μg/L in As. The addition volumes
were 50, 100, 150 and 200 μL; the concentrations added
were therefore 2, 4, 6 and 8 ng/mL, respectively.
The baseline was adjusted with the analytical blank so-
lution i.e., diluted surrogate urine. QC tests were con-
ducted to evaluate the recovery of As from As-spiked
real samples and measurements of secondary standards.
Urine samples of patients underwent the procedures and
analytical methods described above.
Urine and serum creatinine levels and calculation of
creatinine clearance
Levels of urine and serum creatinine were measured
using the Jaffé method [46]. Creatinine clearance rate
(CrCl) was calculated using the Cockcroft–Gault equa-
tion. Serum creatinine is the blood clearance or en-
dogenous blood creatinine depuration [47], their values
were provided by the Oncological Center of Antofagasta
Regional Hospital. Urine and serum CrCl values are used
to evaluate renal dysfunction. The estimated CrCl for
normal renal function should be >80 mL/min [48].
Statistical analyses
Statistical analyses were conducted using the Statistica 9.1
computer programme (StatSoft, Tulsa, OK, USA). p< 0.05
was considered significant.
Results and discussion
Determination of Pt, Se and As
The calibration curves for ICP–OES determinations of
total Pt and Se concentrations in urine were linear. In
the case of Pt, the parameters of the calibration equation
were: intercept = 93.45 counts  s–1; slope of 1.079
counts × s–1/concentration; and r = 0.9998. For Se, the
parameters were: intercept = 55.47 counts  s–1; slope =
1.720 counts × s–1/concentration; and r = 0.9880.
Table 3 Supplied amounts of Pt and Pt, As and Se in 24-h
urine results for the group patients treated with Pt-based
drugs and control group treated without Pt-based drug
and the baseline group (a)
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methodology applied to As urinary analyses were also ana-
lytically suitable: intercept = 0.0375 uA; slope = 0.01615
uA/concentration; and r = 0.9977. The results of the QC
test and analytical validation are presented in Table 2.
The analytical validation and QC results for Pt and Se
by ICP–OES and of As by HGAAS analyses in 24-h
urine samples of cancer patients indicated that the tech-
niques and methodologies applied in the work were ana-
lytically suitable. Surrogate urine prepared from
contaminant-free seawater was important for optimisa-
tion of the analytical parameters and appropriate repre-












Lung X 163.0 35.3 3.62 127.0
Med 156.0 28.2 1.28 23.5
DS 66.6 25.9 6.45 267.0
n 32 32 24 21
Min 39.1 3.94 0.208 1.88
Max 263.0 90.4 22.0 1180.0
Cisplatin
(Group 2)
Other X 174.0 40.1 1.35 216.0
Med 120.0 32.5 1.22 71.0
DS 324.0 36.1 0.717 424.0
n 47 47 36 31
Min 31.6 0.760 0.354 18.8
Max 2297.0 175.0 2.84 2300.0
Carboplatin
(Group 3)
Other X 695.0 262.0 1.59 40.8
Med a a a a
DS 189.0 201.0 0.711 46.9
n 11 11 9 6
Min 433.0 9.80 0.516 2.53
Max 917.0 680.0 2.52 121.0
Control 1
(b) (Group 4)











Med a aInter-element relationship of Pt, As and Se in urine of
cancer patients from the Antofagasta region of Chile
treated with Pt-based drugs
Recent developments in multi-elemental analytical techni-
ques and methodologies have enabled exploration of inter-
elemental relationships and toxicities of essential elements
and heavy metals, that which coexist in environmental and
biological matrices [49-54]. Knowledge in this area is
mainly based upon single elements; a better-known case is
that of As, which has been associated with several diseases,
including cancer [55-58]. However, it has become increas-
ingly clear that simple, single-element models are often in-
adequate to explain the relationship between disease and
nutrition, element toxicity, or deficiency of elements in
food. Improved understanding of the synergistic and/or
antagonistic interactions between trace elements is needed
[59]. A multi-elemental hypothesis may be a better ap-
proach to understand these relationships.
Renal function before and after cancer treatment with
Pt-based drugs is an important parameter. Before start-
ing anti-cancer treatment, it is advisable that the CrCl is
>60 mL/min [47,60]. Patients with lower values have an
increased risk of severe suppression of the bone marrow.
The CrCl for normal renal function is> 80 mL/min
[47,61]. The CrCl values before Pt-based drug chemo-
therapy for the control group 2 (baseline patients; see
below) were 93.3–114.6 mL / min; serum and urine cre-
atinine values were 0.6–0.9 and 0.8–1.1 mg / dL, respect-
ively. Evidently, Pt-based drug chemotherapy impacts the
CrCl and the metal/creatinine quotient values, bothTable 2 Traceability and quality control of urinary













Pt 11 1000 971.0 97.1 5.7 2.9 7.7
Se 11 300 290.9 97.0 6.3 3.0 5.4
As 11 4 3.87 96.7 6.1 3.3 0.22
RSD relative standard deviation; RE relative error; DL detection limit.parameters are considered controversial [62,63]. Accord-
ing this approach, after chemotherapy, 82 of 90 cancer
patients had kidney damage.
Statistical parametric treatment
Tables 3 and 4 shows the main parametric statistic
results found in 24-h urine samples of five cancer patient




Amounts of supplied Pt and Pt, As and Se in 24-h urine samples.
Supp, Supplied; X, mean; Med, Median; SD, Standard deviation; n, number of
cases; Min, Minimum value; Max, Maximum value; (a) due the small number of
cases, the median values were not reported; (b) non platinum drugs treatment;
(c) patients without chemotherapy (two gastric cancer, two bladder cancer and
five lung cancer).
Table 4 Pt, As, and Se amounts in 24-h urine as metal 
(g creatinine)-1results for the group patients treated with
Pt-based drugs and control group treated without











Lung X 1.05 143.0 5.57
Med 1.06 49.0 2.08
DS 0.625 263.0 8.94
n 32 24 21
Min 0.136 7.0 0.360
Max 2.52 1028.0 31.1
Cisplatin
(Group 2)
Other X 1.39 83.9 7.96
Med 0.969 40.7 2.55
DS 1.59 186.0 17.1
n 47 36 31
Min 0.110 11.3 0.280
Max 7.26 1136.0 91.2
Carboplatin
(Group 3)
Other X 13.3 156.0 10.1
Med a a a
DS 9.76 182.0 18.5
n 11 9 6
Min 0.780 25.5 0.40

















Pt, As and Se amounts in 24-h urine samples expressed as metal (g creatinine)–1
Supp, Supplied; X, mean; Med, Median; SD, Standard deviation; n, number of
cases; Min, Minimum value; Max, Maximum value; (a) due the small number of
cases, the median values were not reported; (b) non platinum drugs treatment;
(c) patients without chemotherapy (two gastric cancer, two bladder cancer and
five lung cancer).
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than lung cancer treated with cisplatin; 3) cancer other
than lung cancer treated with carboplatin; 4) cancer
other than lung treated with drugs not containing metals
(control 1); and 5) lung and other than lung cancer be-
fore the chemotherapy began, which can be considered
the baseline group (control 2). The number of patientsin group 3 and in each one of the control groups was
fewer to 11 cancer cases, respectively. Normal distribu-
tion of the data was proven by applying the Shapiro-Wilk
normality test. For groups 1–2 with more than 11 cancer
patient cases, the Shapiro–Wilk normality test was also
applied. One-way ANOVA (p≤ 0.05) test were applied to
determine the level of significance of the data. If the data
of groups 1, 2 followed a normal or a non normal distri-
bution, the most representative group value considered
was the mean or the median, respectively. In Tables 3
and 4 the number of As and Se results are less than the
total number of cancer types (n), because in some urine
samples the amount of elements were below the detec-
tion limit of the applied analytical technique.
Although the number of patient with cancer of the
control groups was low, one can observe that in both
cases the Se levels tend to be higher than those of As.
However, in control group 2, the range of As and Se
levels tends to be comparable or slightly smaller to than
those of control group 1. In Region II (Antofagasta) Se
concentrations have been shown to be higher than those
As in the umbilical cords and placentas of normal and
malformed newborn babies, as well as in the tissues of
patients and in tissues of patients’ subjected to cardiovas-
cular surgeries [64,65]. This characteristics was also
observed in the present study, inasmuch that the Se and
As concentrations in group 3 were comparable with
those of control 1 and control 2 groups.
Figure 1 shows the one-way ANOVA profiles (p≤ 0.05)
for calculated drug supplied Pt and Pt in 24-h urine sam-
ples from lung-cancer patients treated with cisplatin
(group 1); the Shapiro–Wilk normality test parameter
are also shown. The one-way ANOVA urine profiles for
Se of patients other than lung cancer treated with cis-
platin (group 2) did not exhibit significant variations
(p≤ 0.05), but urine profiles of As did (p ≤ 0.05). In both
cases, the data did not follow a normal distribution.
Regarding the calculated drug-supplied platinum and
the Pt, Se and As in urine, the results presented in
Table 3 indicate that the decreasing tendency of supplied
Pt was: carboplatin (cancer other than lung, 695 mg)>
cisplatin (lung cancer, 163 mg)> cisplatin (cancer other
than lung, 120 mg); the tendency of Pt amount in urine
was the same as that of supplied Pt. The tendency of
excreted Se amount in urine was carboplatin (cancer
other than lung, 1.59 μg)> cisplatin (cancer other than
lung, 1.22 μg) cisplatin (lung cancer, 1.28 μg). With re-
spect to excreted As amounts in urine, the tendency was
cisplatin (cancer other than lung, 71 ng)> carboplatin
(cancer other than lung, 40.8 ng)> cisplatin (lung cancer,
23.5 ng). Hence, with Pt –base drugs and chemotherapy
not involving metal-base drugs, Se amounts were always
higher than As amounts in urine. This inter-element re-
lationship suggests that, in general, anti-cancer drugs
Figure 1 a. One-way ANOVA plot (p≤ 0.05) for supplied platinum to lung-cancer patients treated with cisplatin. b. One-way ANOVA plot
(p≤ 0.05) for excreted platinum from supplied platinum-based drug to lung-cancer patients.
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relationship was independent of the nature of the drug
used in the treatment.
The amounts of Pt, As and Se in 24-h urine samples
from cancer patients expressed as metal/g creatinine
showed the same distribution tendency and statistical
significance as non-normalised values (Table 4). The
comparison with metal/g creatinine values for healthy
subjects (i.e., As, 33.3 μg/g creatinine [66,67]; Se,
(women), 9.8 μg/g creatinine; Se (men), 13.5 μg/g cre-
atinine [68]; and Pt, 3.3 ng/g creatinine [69]), along with
the results obtained in this work, revealed that the values
for cancer patients were lower than those for healthy
persons. However, the values obtained for Se and Pt were
higher than the values for healthy persons. The compari-
son of metal/g creatinine values between cancer patients
from this work with those in other studies i.e., As,
116 μg/g creatinine (patients with arsenicism without cu-
taneous lesions); As, 121.2 μg/g creatinine (patients with
arsenicism with skin cancer) [66]; Se, 206.7 μg/g creatin-
ine [70]; and Pt 0.30–4.18 μg/g creatinine [42], indicated
that, in this work, metal/g creatinine-reported values
were lower than those of persons with skin cancer
reported in the literature. For Se, the values reported in
the literature were higher than those reported here and,
for Pt from cisplatin, the values were within the range of
those reported previously. However, in the case of Pt
from carboplatin, the metal/g creatinine values obtained
in this work were approximately threefold higher than
the values in the literature [42]. Owing to a multiplicityof factors involved in creatinine excretion, the analytical
reproducibility of the heavy metal/creatinine quotient
value is not satisfactory; this parameter is also poorly
representative in the clinical scenarios [63].
For 24-h urine samples, there were no significant dif-
ferences between the excreted Pt amounts for lung-cancer
patients and for patients with cancer other than lung
cancer treated with cisplatin despite the significant differ-
ences in the amounts of supplied Pt. Analytically, the ex-
cretion of As was less than of Se, which could suggest
that Pt favours Se excretion.Multivariate statistical treatment
The cluster technique was applied to the involved variables
(i.e., calculated amounts of Pt supplied through Pt-based
drugs and the urinary amounts of Pt, As and Se excreted in
24-h urine after the cancer patients chemotherapy with cis-
platin and carboplatin). Cluster analysis is a multivariate
statistical methodology applied to datasets if there is a lack
of information about the classes comprising the data. The
basic objective is to group the variables by similarities [71].
The technique is based on two aspects: the way the distance
between the variables is measured (metric) and the group-
ings or clusters (linkage or amalgamation rule) [72]. The
technique was applied to the most representative sets of
values in accordance the Shapiro–Wilk normality test.
Ward’s method was applied with Pearson’s 1-r approxima-
tion to measure the distance between variables and the
groupings or clusters.
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http://www.biomedcentral.com/1756-0500/5/207Figure 2a shows the dendrogram of the variables related
to 24-h urine values after the first cycle of treatment with
cisplatin to lung-cancer cases as well as patients with can-
cer other than lung (groups 1, 2). In addition, 4 patients
with ovarian cancer were considered after a second cycle
of treatment. Carboplatin was used to treat only patients
with cancer other than lung cancer, and only one patient
had a second treatment cycle. Figure 2a shows two main
groupings [Pt supplied - Pt excreted] and the amounts of
As and Se excreted [Se, As excreted]. From application of
the bidimensional grouping technique (Figure 2b), the
quantitative extension of supplied Pt and the correspond-
ing excretions of Pt (μg), Se (μg) and As (ng) in urine wereFigure 2 a. Tree diagram of supplied platinum and amounts of excret
patients with lung cancer and cancer other than lung cancer treated
plot for supplied platinum and excreted amounts of platinum, selenium an
cancer other than lung cancer treated with cisplatin and carboplatin.compared. We concluded that urinary excretion of Pt after
the infusion of cisplatin and carboplatin was low in the
short term (even if more than one cycle drug was applied).
Hence, Pt would initially be predominantly distribute and
bio-accumulate in the tissues.
Figures 3a (lung-cancer) and 3b (cancer other than lung
cancer) show the statistical dispersion plots according to
the linear correlation model for the excretion of Se and As
compared with Pt excretion after cisplatin treatment
(groups 1, 2). For lung-cancer patients (Figure 3a), the ten-
dency of As excretion was contrary to the increased excre-
tion of Pt. With regard to Se, only a small group of
patients showed increased excretion of Se accompanied byed platinum, selenium and arsenic in 24-h urine samples of
with cisplatin- and carboplatin-based drugs. b. Two-way joining
d arsenic in 24-h urine samples for patients with lung cancer and
Figure 3 a. Linear dispersion plots for excreted arsenic and selenium amounts versus excreted platinum amount for lung-cancer
patients treated with cisplatin. b. Linear dispersion plots for excreted arsenic and selenium amounts versus excreted platinum amounts for
patients with cancer other than lung cancer treated with cisplatin.
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http://www.biomedcentral.com/1756-0500/5/207increased excretion of Pt. For most cases, Se was distribu-
ted above and below the 95% confidence interval. Accord-
ing to our hypothesis, As excretion (cancer agent) was low
compared with the Se excretion, and was negatively corre-
lated with homeostatic excretion of Pt. Se excretion (pro-
tective agent against cancer) was comparatively higher
than of As, but only a few cases were positively corre-
lated with Pt excretion. Therefore, lung tumours would
bind more strongly to As than Se.
For Pt from cisplatin infused in patients with cancer
other than lung cancer (Figure 3b), excretion of As
increased linearly with increased excretion of Pt, and the
excretion of Se was similar to that described for lung-
cancer patients treated with cisplatin (Figure 3a).
According to our hypothesis, excretion of the cancer
agent (As) compared with the excretion of Se was also
low, but was positively correlated with the homeostatic
excretion of Pt. In turn, the assumed protective agent
against cancer (Se) did not correlate with Pt excretion,
but its level of excretion was higher than seen in lung-cancer patients. In the case of patients with cancer other
than lung cancer treated with carboplatin, the dispersion
plot for excretion of As respect to excreted Pt exhibited
inverse tendency (r =–0.2713), but Se did not correlate
with excreted Pt.
Regard to supplied Pt through cisplatin to patients with
cancer other than lung cancer, excretions of Se and As did
not exhibit any tendencies. However, in the case of Pt sup-
plied through cisplatin to lung-cancer patients, the
excreted As tended to exhibit an inverse linear tendency
(r=–0.2918) with respect to supplied Pt. In turn, with
regard to supplied Pt by treatment with carboplatin in
patients with cancer other than lung cancer, As tended to
exhibit a direct linear tendency (r= 0.3987), and Se tended
to exhibit an inverse linear tendency (r =–0.2388). These
functional inter-element associations can be important for
the hypothesis outlined in the presently work. Therefore,
differences appeared to exist between the relationships and
inter-element associations among As, Se and Pt for
patients treated for lung cancer and those treated for
Román et al. BMC Research Notes 2012, 5:207 Page 10 of 12
http://www.biomedcentral.com/1756-0500/5/207cancer other than lung with Pt-based drugs. However, ei-
ther with Pt-based drugs or those not containing Pt, the
excretion of Se was greater than that of As. This
phenomenon could enhance the effect of carcinogens such
as arsenic, reducing the protective effect of Se, and thereby
lead to metastasis [28,32,73].
Pt and As are not essential elements for humans, but
Se is considered essential and an anti-cancer agent [32].
Consequently, the information obtained in this work
about urinary levels of As, Se and Pt immediately after
cancer patients were subjected to chemotherapy with Pt-
based drugs, could contribute to a better understanding
of the adverse effects of Pt, and help in the more accur-
ate estimation of drug doses [24,74]. Consideration of
urinary levels of carcinogens such as As and cancer-
fighting nutrients such as Se could allow more individua-
lised or dedicated strategies for predictive calculations of
drug dosages to be applied to cancer patients.
A well-established correlation has been found between
As exposure in the Antofagasta region of Chile and the
risk of cancer of the bladder, lung and skin [75]. Conse-
quently, urinary levels of As and Se after each treatment
cycle with Pt-based chemotherapeutic drugs could be
important for a better understanding of the carcinogenic
mechanism of As exposure [76] and about the hypo-
thetic cancer-protective effects of Se. Genetic and epi-
genetic processes appear to be involved in cancer
mechanisms [77,78]. Epigenetic studies focus on the
stress that As provokes in cells without affecting DNA,
but directly influences the genome expression. In this
complementary mechanism, As participates as an ‘oppor-
tunistic carcinogen’ that enhances the genotoxicity and
mutagenicity of other environmental stressors [75]. During
Pt-based drug treatments, patients are exposed to an acute
impact of Pt. This subjects cellular homeostasis to deliber-
ate stress by Pt, inducing toxic and, perhaps hormesic
responses. Among cancer patients exposed chronically to
arsenic and treats with Pt-drugs based, Se, As and Pt can
participate synergistically in the regulated and unregulated
activation of apoptosis, phagocytosis, and cellular homeo-
stasis involved in toxicological and hormesis mechanisms
[18,20,77,79-81].Conclusions
Overall, despite significant variation in Pt amounts sup-
plied from Pt-based drugs, the amounts of Pt in 24 hours
urine samples were not significantly different between
patients with lung cancer and those with other cancers
treated with cisplatin. With respect to the baseline status
of patients, the analytical amounts of excreted Se were
greater than those for As, particularly, for cisplatin chemo-
therapy. This finding could imply that, with regard to As
displacement, Pt favours the excretion of Se. For othertypes of cancers treated with drugs without Pt, excretion of
Se was also greater than that of As, suggesting an antagon-
ist Se–anti-cancer drug relationship. Conversely, cisplatin
displaces more As in patient with other cancers than lung
cancer and more Se in patient with lung cancer. Whether
or not they satisfied a linear mathematical model, there
seem to have differences among the As - Se - Pt inter-
element relationships according to cancer type.
The knowledge obtained in this work, can contribute to
understanding the cancer mechanism of As and the As -
Se - Pt inter-element association for lung cancer as well as
other types of cancer. Elements with similar electron
arrangements as the As - Se pair are often antagonists in
biological systems [82], which can be rationalised by the
Hard/Soft/Acid/Base principle, [83]. The antagonism and/
or synergism among these elements can be intrinsic to the
cancerous metalloid-dependent mechanism of the As-Se
pair, and exogenic Pt participation in healing, cancer
propagation or metastasis. Further research including
more elements is in progress.
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